리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 98 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 폐암 검진 소프트웨어 시장은 2030년까지 4,050만 달러에 달할 전망
2024년에 2,840만 달러로 추정되는 세계의 폐암 검진 소프트웨어 시장은 2030년에는 4,050만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 6.1%로 성장할 것으로 예측됩니다.
미국 시장은 750만 달러로 추정, 중국은 CAGR 6.0%로 성장 예측
미국의 폐암 검진 소프트웨어 시장은 2024년에 750만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 650만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 5.7%와 5.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%로 성장할 것으로 예측됩니다.
폐암 검진 소프트웨어 세계 시장 - 조기 발견·진단에 혁명을 가져온다
폐암 검진 소프트웨어가 인기를 끄는 이유는?
폐암은 전 세계 암 관련 사망의 주요 원인 중 하나이며, 발견이 늦어져 사망률이 높습니다. 조기 진단을 통해 생존율이 크게 향상되었으며, 폐암 검진 소프트웨어는 발견의 정확성과 효율성을 높이는 중요한 툴로 부상하고 있습니다. 의료 영상 진단에 인공지능(AI)과 머신러닝(ML)을 도입하는 것은 방사선과 전문의와 종양 전문의가 폐 결절을 보다 정확하게 식별할 수 있도록 도와 시장을 주도하고 있습니다. 장기 흡연자 등 고위험군을 대상으로 한 정부의 구상과 검진 프로그램은 첨단 검진 솔루션에 대한 수요를 더욱 증가시키고 있습니다. 폐암 검진 소프트웨어가 병원의 방사선과와 원격의료 플랫폼에 통합되면서 조기 발견이 더욱 친숙하고 효과적으로 이루어지고 있습니다.
혁신은 폐암 검진 소프트웨어의 성능을 어떻게 향상시키고 있는가?
AI 기반 알고리즘과 딥러닝 모델의 통합으로 폐암 검진 소프트웨어의 정확도가 크게 향상되었습니다. 이러한 기술은 작은 결절도 감지하여 영상 분석을 강화하여 진단의 위양성 및 위음성을 감소시킵니다. 클라우드 기반 검진 플랫폼과 원격의료 통합을 통해 특히 원격지나 의료 서비스가 부족한 지역에서 검진 서비스에 대한 접근성이 확대되고 있습니다. 예측 분석의 도입은 의사가 환자의 위험 요인을 평가하고 추가 평가를 위해 고위험 사례의 우선순위를 정하는 데 도움이 되고 있습니다. 또한 폐암 검진 소프트웨어와 전자의무기록(EHR)을 결합하여 워크플로우의 효율성을 높이고, 실시간 데이터 분석 및 자동화된 보고서 작성을 가능하게 합니다.
시장 성장 촉진요인은?
폐암 검진 소프트웨어 시장의 성장을 가속하는 몇 가지 요인이 있습니다. 폐암의 유병률 증가와 조기 발견에 대한 중요성이 높아진 것이 주요 촉진요인입니다. 특히 선진국에서는 폐암 검진 프로그램을 지원하는 정부 규제와 헬스케어 정책으로 인해 폐암 검진 프로그램 도입이 가속화되고 있습니다. 헬스케어 분야에서 AI와 자동화의 활용이 확대되고, 디지털 헬스 기술에 대한 투자가 증가함에 따라 정교한 스크리닝 솔루션에 대한 수요가 더욱 증가하고 있습니다. 또한 클라우드 기반 의료용 영상처리 플랫폼의 확대와 소프트웨어 개발자와 의료 서비스 프로바이더와의 협업 증가가 시장 개발에 기여하고 있습니다.
과제와 미래 기회는?
폐암 검진 소프트웨어 시장은 그 잠재력에도 불구하고 높은 도입 비용, 데이터 프라이버시 문제, 기존 헬스케어 IT 시스템과의 상호운용성 문제 등의 문제에 직면해 있습니다. 또한 수작업에 의한 영상 분석에 의존하는 기존 영상의학과 의사들의 저항도 채택을 지연시킬 수 있습니다. 그러나 AI 지원 진단의 수용 확대, 보다 비용 효율적인 클라우드 기반 솔루션의 개발, 법규 준수의 진전으로 인해 큰 비즈니스 기회가 창출되고 있습니다. 향후 시장 성장의 원동력은 AI를 활용한 실시간 진단, 유전적 요인 및 생활습관 요인에 기반한 개인 맞춤형 검진 프로토콜, 폐암 검진 소프트웨어의 모바일 헬스 용도에 대한 통합입니다.
부문
단일 부문
조사 대상 기업의 예
C the Signs
Canon Medical Systems Corporation
Dxcover Ltd
Eon
FUJIFILM Holdings Corporation
Guardant Health
iDNA
ITK-SNAP
Koninklijke Philips N.V.
MagView
Medtronic
MRS Systems, Inc.
Nuance Communications, Inc.
Oatmeal Health
Optellum
PenRad Technologies, Inc.
Siemens Healthineers AG
Thynk Health
Volpara Health
VoxelCloud
AI 통합
우리는 검증된 전문가 컨텐츠와 AI 툴에 의해 시장과 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM에 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Lung Cancer Screening Software Market to Reach US$40.5 Million by 2030
The global market for Lung Cancer Screening Software estimated at US$28.4 Million in the year 2024, is expected to reach US$40.5 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030.
The U.S. Market is Estimated at US$7.5 Million While China is Forecast to Grow at 6.0% CAGR
The Lung Cancer Screening Software market in the U.S. is estimated at US$7.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Global Lung Cancer Screening Software Market - Revolutionizing Early Detection and Diagnosis
Why Is Lung Cancer Screening Software Gaining Popularity?
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with a high mortality rate due to late-stage detection. Early diagnosis significantly improves survival rates, and lung cancer screening software is emerging as a crucial tool in enhancing detection accuracy and efficiency. The adoption of artificial intelligence (AI) and machine learning (ML) in medical imaging is driving the market, as these technologies help radiologists and oncologists identify lung nodules with greater precision. Government initiatives and screening programs aimed at high-risk populations, such as long-term smokers, are further propelling the demand for advanced screening solutions. The increasing integration of lung cancer screening software into hospital radiology departments and telemedicine platforms is making early detection more accessible and effective.
How Are Innovations Enhancing the Performance of Lung Cancer Screening Software?
The integration of AI-driven algorithms and deep learning models is significantly improving the accuracy of lung cancer screening software. These technologies enhance image analysis by detecting even the smallest nodules, reducing false positives and false negatives in diagnosis. Cloud-based screening platforms and telemedicine integration are expanding access to screening services, particularly in remote and underserved areas. The adoption of predictive analytics is helping physicians assess patient risk factors and prioritize high-risk cases for further evaluation. Additionally, the combination of lung cancer screening software with electronic health records (EHRs) is streamlining workflow efficiency, allowing for real-time data analysis and automated reporting.
What Are the Key Market Drivers?
Several factors are fueling the growth of the lung cancer screening software market. The rising prevalence of lung cancer and the increasing emphasis on early detection are key drivers. Government regulations and healthcare policies supporting lung cancer screening programs, particularly in developed nations, are accelerating adoption rates. The growing use of AI and automation in healthcare, along with increasing investments in digital health technologies, is further boosting the demand for sophisticated screening solutions. Additionally, the expansion of cloud-based medical imaging platforms and the increasing collaboration between software developers and healthcare providers are contributing to market growth.
What Challenges and Future Opportunities Exist?
Despite its potential, the lung cancer screening software market faces challenges such as high implementation costs, data privacy concerns, and interoperability issues with existing healthcare IT systems. Resistance from traditional radiologists who rely on manual image analysis may also slow down adoption. However, the growing acceptance of AI-assisted diagnostics, the development of more cost-effective cloud-based solutions, and advancements in regulatory compliance are creating significant opportunities. Future growth in the market will be driven by AI-powered real-time diagnosis, personalized screening protocols based on genetic and lifestyle factors, and the integration of lung cancer screening software into mobile health applications.
SCOPE OF STUDY:
The report analyzes the Lung Cancer Screening Software market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Single Segment
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 36 Featured) -
C the Signs
Canon Medical Systems Corporation
Dxcover Ltd
Eon
FUJIFILM Holdings Corporation
Guardant Health
iDNA
ITK-SNAP
Koninklijke Philips N.V.
MagView
Medtronic
MRS Systems, Inc.
Nuance Communications, Inc.
Oatmeal Health
Optellum
PenRad Technologies, Inc.
Siemens Healthineers AG
Thynk Health
Volpara Health
VoxelCloud
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Lung Cancer Screening Software - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Lung Cancer Incidence Rates Throws the Spotlight on Early Detection and Screening Solutions
Growing Emphasis on Precision Medicine Propels Demand for AI-Driven Lung Cancer Screening Software
Increasing Government-Led Screening Programs Expands Addressable Market Opportunity for Lung Cancer Detection Tools
Escalating Awareness Campaigns on Smoking Risks Drives Adoption of Preventive Screening Technologies
Advancements in AI and Deep Learning Algorithms Strengthen the Business Case for Automated Lung Nodule Detection
Integration of Lung Cancer Screening Software into Radiology Workflows Accelerates Demand Among Hospitals and Imaging Centers
Cloud-Based Diagnostic Platforms Sustain Growth in Remote Screening and Teleradiology Markets
Reimbursement Reforms and Coverage Expansion in Developed Markets Drive Commercial Adoption
Surge in Geriatric Population at High Risk of Lung Cancer Spurs Demand for Preventive Screening Tools
Rapid Uptake of Low-Dose CT (LDCT) in Routine Clinical Practice Fuels Growth of Compatible Screening Software
Expansion of National Screening Guidelines Across Key Markets Boosts Software Deployment
Enhanced Image Processing Capabilities and 3D Visualization Drives Market Penetration in Oncology Imaging
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Lung Cancer Screening Software Market Analysis of Annual Sales in US$ for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Lung Cancer Screening Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Lung Cancer Screening Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 5: USA Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 6: USA Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
CANADA
TABLE 7: Canada Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 8: Canada Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
JAPAN
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 9: Japan Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 10: Japan Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
CHINA
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 11: China Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 12: China Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
EUROPE
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 13: Europe Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 14: Europe Historic Review for Lung Cancer Screening Software by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 15: Europe 15-Year Perspective for Lung Cancer Screening Software by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
FRANCE
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 16: France Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 17: France Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
GERMANY
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 18: Germany Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 19: Germany Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
ITALY
TABLE 20: Italy Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 21: Italy Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
UNITED KINGDOM
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 22: UK Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 23: UK Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
REST OF EUROPE
TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 25: Rest of Europe Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
ASIA-PACIFIC
Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 27: Asia-Pacific Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
REST OF WORLD
TABLE 28: Rest of World Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 29: Rest of World Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR